Latest Insider Transactions at Tenaya Therapeutics, Inc. (TNYA)
This section provides a real-time view of insider transactions for Tenaya Therapeutics, Inc. (TNYA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Tenaya Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Tenaya Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
SELL
Open market or private sale
|
Direct |
2,258
-3.57%
|
$4,516
$2.12 P/Share
|
|
Aug 16
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
SELL
Open market or private sale
|
Direct |
2,363
-1.22%
|
$4,726
$2.89 P/Share
|
|
Aug 16
2024
|
Faraz Ali Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,748
-2.49%
|
$19,496
$2.89 P/Share
|
|
Aug 16
2024
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,428
-3.28%
|
$14,856
$2.89 P/Share
|
|
Aug 15
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+27.59%
|
-
|
|
Mar 05
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,300
-1.33%
|
$23,100
$7.0 P/Share
|
|
Feb 23
2024
|
Leone D Patterson Chief Fin. and Bus. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+26.77%
|
-
|
|
Feb 23
2024
|
Whittemore Tingley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+24.38%
|
-
|
|
Feb 23
2024
|
Timothy Hoey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+4.79%
|
-
|
|
Feb 23
2024
|
Faraz Ali Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+30.03%
|
-
|
|
Feb 20
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,569
-1.35%
|
$32,845
$5.74 P/Share
|
|
Feb 16
2024
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,500
-8.12%
|
$32,500
$5.86 P/Share
|
|
Feb 16
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,681
-1.89%
|
$23,405
$5.86 P/Share
|
|
Feb 16
2024
|
Faraz Ali Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,358
-5.32%
|
$31,790
$5.86 P/Share
|
|
Feb 16
2024
|
Leone D Patterson Chief Fin. and Bus. Officer |
SELL
Open market or private sale
|
Direct |
5,201
-7.89%
|
$26,005
$5.86 P/Share
|
|
Feb 12
2024
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
2,222,222
+14.05%
|
$8,888,888
$4.5 P/Share
|
|
Feb 12
2024
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
2,222,222
+14.05%
|
$8,888,888
$4.5 P/Share
|
|
Aug 29
2023
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,243
-2.84%
|
$28,972
$4.26 P/Share
|
|
Aug 16
2023
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,007
-1.55%
|
$12,021
$3.81 P/Share
|
|
Aug 16
2023
|
Faraz Ali Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,563
-4.45%
|
$16,689
$3.81 P/Share
|
|
Aug 16
2023
|
Leone D Patterson Chief Fin. and Bus. Officer |
SELL
Open market or private sale
|
Direct |
4,452
-6.45%
|
$13,356
$3.81 P/Share
|
|
Aug 16
2023
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,563
-6.78%
|
$16,689
$3.81 P/Share
|
|
Mar 10
2023
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
6,779
+0.06%
|
$13,558
$2.6 P/Share
|
|
Mar 10
2023
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
6,779
+0.06%
|
$13,558
$2.6 P/Share
|
|
Feb 15
2023
|
Leone D Patterson Chief Fin. and Bus. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+41.35%
|
-
|
|
Feb 15
2023
|
Whittemore Tingley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+43.0%
|
-
|
|
Feb 15
2023
|
Timothy Hoey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+11.0%
|
-
|
|
Feb 15
2023
|
Faraz Ali Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Feb 08
2023
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+11.65%
|
$3,000,000
$2.6 P/Share
|
|
Feb 08
2023
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+11.65%
|
$3,000,000
$2.6 P/Share
|
|
Jan 19
2023
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
69,739
+0.7%
|
$139,478
$2.5 P/Share
|
|
Jan 19
2023
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
69,739
+0.7%
|
$139,478
$2.5 P/Share
|
|
Jan 18
2023
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
135,688
+1.37%
|
$271,376
$2.52 P/Share
|
|
Jan 18
2023
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
135,688
+1.37%
|
$271,376
$2.52 P/Share
|
|
Jan 17
2023
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
49,463
+0.51%
|
$98,926
$2.49 P/Share
|
|
Jan 17
2023
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
49,463
+0.51%
|
$98,926
$2.49 P/Share
|
|
Nov 21
2022
|
Deepak Srivastava |
BUY
Open market or private purchase
|
Indirect |
230,769
+38.26%
|
$461,538
$2.6 P/Share
|
|
Nov 21
2022
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
9,615,384
+50.0%
|
$19,230,768
$2.6 P/Share
|
|
Nov 21
2022
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
9,615,384
+50.0%
|
$19,230,768
$2.6 P/Share
|
|
Nov 17
2022
|
Eli Casdin Director |
BUY
Open market or private purchase
|
Indirect |
2,492,042
+29.08%
|
$4,984,084
$2.6 P/Share
|
|
Apr 26
2022
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,353
-0.68%
|
$13,530
$10.13 P/Share
|
|
Aug 03
2021
|
Jeen Joo Kang Director |
BUY
Conversion of derivative security
|
Direct |
12,500
+33.33%
|
-
|
|
Aug 03
2021
|
David V Goeddel |
BUY
Conversion of derivative security
|
Indirect |
9,346,124
+49.86%
|
-
|
|
Aug 03
2021
|
Eli Casdin Director |
BUY
Conversion of derivative security
|
Indirect |
2,736,818
+50.0%
|
-
|
|
Aug 03
2021
|
Eli Casdin Director |
BUY
Open market or private purchase
|
Indirect |
850,000
+20.86%
|
$12,750,000
$15.0 P/Share
|
|
Aug 03
2021
|
Column Group Iii Gp, LP |
BUY
Conversion of derivative security
|
Indirect |
9,346,124
+49.86%
|
-
|
|
Aug 03
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,736,818
+50.0%
|
-
|
|
Aug 03
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
850,000
+20.86%
|
$12,750,000
$15.0 P/Share
|